C2-Incidencia
April 19, 2018 | Author: Anonymous | Category: N/A
Short Description
Download C2-Incidencia...
Description
Incidencia de las enfermedades hematológicas malignas en Europa por subtipos morfológicos : resultados del proyecto HAEMACARE Pr Marc Maynadié Registre des Hémopathies Malignes de Côte d’Or EA 4184 – Université de Bourgogne
Proyecto financiado por la Comunidad Europea Para aumentar la disponibilidad y la estandarización de datos de registros en Europa Iniciado dentro del programa EUROCARE IV (93 Registros europeos) HAEMACARE : 44 registros - 20 países - 2000-2002 - > 97 000 casos
5 regiones :
Norte : países nórdicos Inglaterra y Irlanda : UK Centro : Francia, Alemania, Bélgica, Holanda,.. South : España, Portugal Italia, Malta,….
Groupos de enfermedades
• Usar la ICD-O-3 para analizar los datos • Hacer grupos de enfermedades para conducir análisis de sobrevivencia a diferente nivel de detalles • Grupaje con hierarchia : estrategia usada en el consorcio INTERLYMPH (Morton L et al, Blood, 2007)
Hierarchical group ICD-O-2 codes* WHO categories
ICD-O-3 codes
Classical Hodgkin lymphoma, lymphocyte-rich 9651 Classical Hodgkin lymphoma, mixed cellularity 9652 Classical Hodgkin lymphoma, lymphocytedepleted 9653-9655 Classical Hodgkin lymphoma, nodular sclerosis 9663-9667 Classical Hodgkin lymphoma, NOS Nodular lymphocyte predominant Hodgkin lymphoma
1
2
3
4
5
HL-C
HL-CLR/MC/LD
HL-C-LR
LN HL
HL-C
HL-CLR/MC/LD
HL-C-MC -
LN HL
HL-C
HL-CLR/MC/LD
HL-C-LD -
LN HL
HL-C
HL-C-NS
-
-
LN HL
HL-C
-
-
-
LN HL
HL-NLP
-
-
-
9657, 9658 LN HL 9652
6
9653-9655
9663-9667 9650, 9661, 9662
9650, 9661, 9662 9659, 9660 9659
Morton L et al, Blood, 2007 Turner JJ et al, Blood, 2011
Linfoma de Hodgkin Crude incidence rate/100 000inh/y
by region
by age
HL NOS/classical HL, lymphocyte- rich
2
HL, lymphocyte depletion
Crude Incidence Rates x 100,000
HL, nodular sclerosis
1.5
1
0.5
0
1990
1991
1992
1993
1994
1995
Year of diagnosis
1996
1997
1998
1999
2000
2001
2002
Incidence and mortality estimates in France by Hodgkin L Scenario= C ==> Figure 3: Tendance chronologique pour la France
1980
1985
1990
1995 Année
2000
2005
2010
50.0
50.0
10.0 1.0 0.1
0.5
1.0
5.0
10.0 0.5 0.1
Incidence estimée Homme Incidence estimée Femme Mortalité estimée Mortalité observée
5.0
0.5 1.0 5.0 10.0 T aux standardisés m onde (échelle log) 0.1
10.0 5.0 1.0 0.5 0.1
T aux standardisés m onde (échelle log)
50.0
Femme
50.0
Homme
1980
1985
1990
1995 Année
2000
2005
2010
ICD-0-3 code
L de las celulas B maduras
N° de casos
Todos
Hombres
Mujeres
42 855
19.14
21.30
17.07
LLC/SLL
9670/9823
11 019
4.92
5.97
4.01
L Follicular
9690,9691, 9695,9698
4 881
2.19
2.1
2.26
L BDGC
9675, 9678, 9679, 9680, 9684
8 538
3.81
4.06
3.57
L Zona Marginal
9689, 9699, 9764
950
0.42
0.40
0.45
Enfermedades Immunoproliferativas
9671, 9760, 9761, 9762
1859
0.83
1.00
0.67
L de las c. del Manteau
9673
1012
0.45
0.64
0.27
ICD-0-3 code
L de celulas B maduras
N° de casos
All
Hombres
Mujeres
42 855
19.14
21.30
17.07
Mieloma
9732
12 192
5.44
5.85
5.06
Leucemia de Plasmocytos
9733
92
0.04
0.04
0.05
Plasmacytoma
9731, 9734
1172
0.52
0.58
0.47
Burkitt L/L
9687, 9826
488
0.22
0.31
0.13
Leucemia B
9833, 9940
652
0.29
0.46
0.13
by age
Leucemia linfoide Cronica 8
North UK 7
East Central South
Crude Incidence Rates x 100,000
6
5
4
3
2
1
0 1990
1991
1992
1993
1994
1995
1996
Year of diagnosis
1997
1998
1999
2000
2001
2002
Lymphoplasmacytic Lymphoblastic Lymphoma Burkitt
T lymphoma cutaneous
0.95
Other T cell lymphomas
0.9
Other specified NHL
0.85
Mantle cell/centrocytic
0.8
Marginal zone B cell/MALT mucose associated
0.75
Composite Hodgkin and NHL
0.7 0.65 0.6 0.55 0.5 0.45 0.4 0.35
0.3 0.25 0.2
0.15 0.1 0.05
0
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002 Year of diagnosis
Evolución de la incidencia por tipo 4 3,5 3 2,5 2 1,5 1 0,5 0 1980-1984
1985-1989
L. Lymphoplasmocytaires L. Folliculaire L. de Burkitt LNH T
1990-1994
1995-1999
2000-2005
L. du Manteau L. B diffus à grandes cellules L. de la zone marginale
Données RHEMCO 1980-2005
20 18
Crude Incidence Rates x 100,000
16 14 12
hodgkin disease non hodgkin lymphoma
10 8
6 4 2 0
1990
1991
1992
1993
1994 1995 1996 Year of diagnosis
1997
1998
1999
2000
2001
2002
Incidence and mortality estimates in France by NHL Scenario= A ==> Figure 3: Tendance chronologique pour la France
1985
1990
1995
2000
2005
2010
Année
1980-2005 : 2000-2005 :
50 5
10
50 10 5
1
1 1980
Incidence estimée Homme Incidence estimée Femme Mortalité estimée Mortalité observée
1
5 10 Taux standardisés m onde (échelle log)
10 5 1
Taux standardisés m onde (échelle log)
50
Femme
50
Homme
1980
1985
1990
1995
2000
Année
+2.7% /y in men -0.1%/y in men
+2.9%/y in women +0.4%/y in women
2005
2010
Level 1
Level 2
Level 3 recurrent genetic abnormalities
level 4 t(8;21) inv(16) t(15;17) t(9;11) t(6;9) inv(3) or t(3;3) t(1;22) mutated NPM1 mutated CEBPA
with multilineage disorders AML-MDS therapy related
Myeloid Haemopathies
Acute Myeloid Leukaemia AML NOS
Minimaly differentiated without maturation with maturation myelomonocytic monocytic/monoblastic erythoblastic megakaryoblastic basophilic A panmyelosis with myelofibrosis
myeloid sarcoma M Prol with Down Syndrome Blastic plasmacytoid dendritic cell
Myeloid leuk
AL of ambiguous lineage CML Polycythemia vera Essential Thrombocytemia Chronic idiopathic myelofibrosis
Myeloproliferative neoplasms Mastocytosis others Refractory Anaemia Refractory neutropenia Refractory thrombocytopenia RA with ring sideroblasts
Myelodysplastic syndromes
Myelodysplastic/ Myeloproliferative neoplasms Prolif with PDGFRA, PDGFRB or FGFR1
RA with excess of blasts 5q- syndrome R Cytopenia with multilin. Dysplasia Others CMML JCMML atypical CML others
Systematic mastocytosis Mast cell leukemia Mast cell sarcoma
Leucemia mieloide aguda
North UK
6
East Central South
Crude Incidence Rates x 100,000
5
4
3
2
1
0 1990
1991
1992
1993
1994
1995
1996
Year of diagnosis
1997
1998
1999
2000
2001
2002
Leucemia mieloide cronica
North UK 3
East Central
Crude Incidence Rates x 100,000
2.5
South
2
1.5
1
0.5
0 1990
1991
1992
1993
1994
1995
1996
Year of diagnosis
1997
1998
1999
2000
2001
2002
Leukemia NOS Lymphatic Leukemia NOS
Leucemias
Acute Myeloid Leukemia Chronic myeloprolipherative disorders Mature B cell Leukemia Mature cell T/NK cell Leukemia Acute (precursor cell) Lymphatic Leukemia Myelodisplastic syndrome
Crude Incidence Rates x 100,000
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
Dr Milena Sant Dr Claudia Allemani Dr Carmen Tereanu Dr Franco Berrino Istituto dei tumori Milan, Italia
Dr Roberta De Angelis Dr Roberto Capocaccia Ariana Simonetti Istituto Superiore di Sanità Roma, Italia Dr Rafael Marcos Gragera Girona, Espana
Dr Otto Visser Holanda
Dr Jean Michel Lutz Nicer, Suissa The HAEMACARE Group
Pr Marc Maynadié Dijon, Francia
View more...
Comments